Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 5/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.59 |
| ▸ | HTR2A | P28223 | 11/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6000287 | 0.82 | RHEB (0.66) | RHEBSLC6A4KCNH2HTR2A | |
| SCHEMBL6000210 | 0.81 | SLC6A4 (0.56) | RHEBSLC6A4KCNH2HTR2ASLC6A2 | |
| SCHEMBL20536492 | 0.80 | RHEB (1.00) | RHEB | |
| SCHEMBL5502146 | 0.78 | SLC6A4 (0.59) | RHEBSLC6A4KCNH2HTR2ASLC6A2 | |
| SCHEMBL20535781 | 0.77 | RHEB (1.00) | RHEBSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL5501242 | 0.75 | SLC6A4 (0.67) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL5999724 | 0.75 | HTR2A (0.67) | SLC6A4KCNH2HTR2A | |
| SCHEMBL1499400 | 0.74 | RHEB (0.73) | RHEBSLC6A3 | |
| SCHEMBL5999623 | 0.74 | SLC6A4 (0.57) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL16632580 | 0.73 | RHEB (0.63) | RHEBSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | RHEB 2914/4885SLC6A4 150/4885KCNH2 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.